Eli Lilly & Co (LLY) DIvidends Date & History

Key Takeaways

• Eli Lilly and Company (LLY) offers a modest dividend yield of approximately 0.60% with an annual payout of $6.92 per share.
• The company pays dividends quarterly and has increased its dividend for 12 consecutive years.
• Payout ratio stands at a low 22.1%, indicating strong earnings coverage and sustainability.
• Recent dividend growth averages around 15%, supported by robust free cash flow generation.
• LLY suits dividend growth investors seeking long-term compounding over high current income.
• Strong financial position positions the company well for future dividend increases.

Dividend Overview

Eli Lilly and Company (LLY) maintains a conservative dividend policy focused on consistent quarterly payments and long-term growth. The current quarterly dividend is $1.73 per share, translating to an annualized total of $6.92. This results in a forward dividend yield of about 0.60%. Classified as a dividend growth stock rather than a high-yield name, LLY prioritizes reinvestment in its pharmaceutical pipeline while returning capital to shareholders at a measured pace. The low yield reflects the company’s premium valuation and growth-oriented business model in the healthcare sector.

Dividend History and Growth

Eli Lilly and Company (LLY) has a solid track record of dividend growth, with increases for 12 consecutive years. Over the past three years, the average annual dividend growth rate has reached approximately 15.3%, while the five-year rate stands near 15.2%. The company has delivered consistent quarterly payments without cuts, aligning with a strategy of sustainable increases tied to earnings expansion. This streak underscores management’s commitment to rewarding shareholders as the firm scales its innovative drug portfolio.

Dividend Sustainability and Payout Ratio

The dividend appears highly sustainable, backed by a low payout ratio of 22.1%. This leaves substantial room for earnings coverage and potential future raises. Strong free cash flow generation further supports the payout, with projections indicating significant growth in cash availability over the coming years. Low leverage and a robust balance sheet enhance overall financial stability, reducing the risk of dividend interruptions even amid industry volatility or R&D investments.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, Eli Lilly and Company (LLY)’s 0.60% yield is below many large-cap peers such as Pfizer (PFE) and Merck (MRK), which typically offer higher current yields. However, LLY’s superior dividend growth rate and lower payout ratio distinguish it as a growth-oriented player. Investors seeking immediate income may favor higher-yielding competitors, while those prioritizing capital appreciation and rising payouts often view LLY favorably relative to the sector average.

AI Screener

AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Is This Stock Attractive for Dividend Investors?

Eli Lilly and Company (LLY) appeals primarily to dividend growth investors and long-term shareholders who value compounding through rising payouts over high current yields. Its low payout ratio and consistent growth history make it suitable for conservative portfolios seeking stability alongside appreciation potential. Income-focused investors prioritizing higher yields may find better options elsewhere in the sector. Overall, LLY offers a balanced profile for those with a multi-year horizon who appreciate a company with strong earnings momentum and disciplined capital return policies. This analysis does not constitute investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations